Last updated on September 2017

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer


Brief description of study

The purpose of this study is to determine whether the combination of palbociclib with cetuximab is superior to cetuximab in prolonging overall survival in HPV-negative, cetuximab-naive patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Clinical Study Identifier: NCT02499120

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

State Budgetary Healthcare Institution "Oncology Center #2" of the Ministry of
Sochi, Russian Federation
0.48miles
  Connect »